Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: A preliminary report

Japanese Journal of Clinical Oncology

Volumn 35, Issue 2, 2005, Pages 79-83

  Takahashi, Satoru ^a   Suzuki, Makoto ^a   Kume, Haruki ^a   Matsumoto, Shinya ^a   Okamoto, Naohiko ^a   Nishimatsu, Hiroaki ^a   Tomita, Kyoichi ^a   Kitamura, Tadaichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cisplatin; Docetaxel; Ifosfamide; Metastatic urothelial cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; METHOTREXATE; VINBLASTINE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FOOT DISEASE; GRANULOCYTOPENIA; HEALTH STATUS; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; METASTASIS; PARESTHESIA; PERFORMANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PILOT STUDY; PLEURA EFFUSION; SYMPTOMATOLOGY; THROMBOCYTOPENIA; URINARY TRACT CARCINOMA; UROGENITAL TRACT TUMOR; WORLD HEALTH ORGANIZATION; AGRANULOCYTOSIS; ANEMIA; BONE TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; LUNG TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; SOFT TISSUE TUMOR; URINARY TRACT CANCER;

AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; SOFT TISSUE NEOPLASMS; TAXOIDS; THROMBOCYTOPENIA; UROLOGIC NEOPLASMS;

EID: 15044347559     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyi023     Document Type: Article

References (18)

1. Sternberg C, Yakoda A, Scher HI, Watson RC, Herr HW, Morse MJ, et al. M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139:461-9.
2. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. J Clin Oncol 1992; 10:1066-73.
3. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-5.
4. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-70.
5. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15:1853-7.
6. Dimopoulos MA, Deliveliotis C, Moulopoulos LA, Papadimitriou C, Mitropoulos D, Anagnostopoulos A, et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology 1998;52:56-60.
7. Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 1999;54 (Suppl 6A):22-9.
8. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of micro-tubule integrity. Cancer Res 1997;57:229-33.
9. Vasey PA. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J Clin Oncol 2003;21:136-44.
10. Bajorin DF, McCaffrey JA, Hilton S, Mazumdar M, Kelly WK, Scher HI, et al. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. J Clin Oncol 1998;16:2722-7.
11. Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. Jpn J Clin Oncol 1998; 28:497-501.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
13. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 1989;142:289-92.
14. Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cisplatinum-based chemotherapy. J Urol 1994;151:598-600.
15. de Wit R, Kruit W, Stoter G, de Boer M, Kerger J, Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in nonchemotherapy-pretreated patients. Br J Cancer 1998; 78:1342-5.
16. Dimopoulos MA, Bakoyiannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 1999;10:1385-8.
17. Garcia del Muro X, Marcuello E, Guma J, Paz-Ares L, Climent MA, Carles J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002;86: 326-30.
18. Pectasides D, Visvikis A, Aspropotamitis A, Halikia A, Karvounis N, Dimitriadis M, et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Eur J Cancer 2000;36:74-9.